The Avithrapid consortium successfully passed the interim review after an in-depth interview with the evaluators in September. In the consolidated report, the reviewers acknowledged that “the project has achieved most of its objectives and milestones for the period, with relatively minor deviations” and “has delivered significant results in evaluating antiviral compounds, identifying promising candidates against dengue and SARS-CoV-2 viruses”. It is contributing to “the development of peptide–porphyrin conjugates and an innovative AI/ML platform for drug discovery“. As a result, the development of rapid antiviral
workflow “may increase preparedness capabilities for future outbreaks“. In parallel and as added value, the consortium “has carried out outstanding dissemination and outreach activities through various channels, promoting public engagement”.
This positive outcome marks an important milestone — validating AVITHRAPID’s approach and motivating all partners to accelerate the next phase of implementation.